Previous studies evaluating intravitreal ranibizumab and aflibercept for diabetic macular edema show that these anti-VEGF therapies can lead to improvement in Diabetic Retinopathy Severity Score (DRSS) [11, 12, 15–17]. The gene discussed is VEGFA; the disease is diabetic macular edema.